These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2491929)

  • 41. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
    Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
    Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New alternatives and strategies in the treatment of inhibitors.
    Hoyer LW
    Prog Clin Biol Res; 1984; 150():367-72. PubMed ID: 6431440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Inhibitors and "bypass" therapy in hemophilia].
    Fukutake K; Fukutake K
    Nihon Rinsho; 1981; 39(12):3688-99. PubMed ID: 6803034
    [No Abstract]   [Full Text] [Related]  

  • 44. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies to HIV in Israeli hemophiliacs: relationship between serological profile and disease development.
    Orgad S; Malone G; Zaizov R; Marinowitz U; McLane MF; Umiel T; Cohen IJ; Vogel R; Cohen-Avishai O; Ramot B
    AIDS Res Hum Retroviruses; 1987; 3(3):323-32. PubMed ID: 3124874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 47. [Secondary effects of transfusions in hemophiliacs].
    Allain JP
    Rev Fr Transfus Immunohematol; 1979 Feb; 22(1):77-81. PubMed ID: 493793
    [No Abstract]   [Full Text] [Related]  

  • 48. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.
    Hilgartner MW; Knatterud GL
    Blood; 1983 Jan; 61(1):36-40. PubMed ID: 6401216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controlled clinical trials with prothrombin complex concentrates.
    Lusher JM
    Prog Clin Biol Res; 1984; 150():277-90. PubMed ID: 6431433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hemophilia and HTLV-III infection].
    Lechler E
    Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 52. Distribution of the level of antibody to AIDS-associated virus (LAV) in sera from AIDS or AIDS related complex and Japanese hemophiliacs infected with AIDS-associated virus.
    Tsuchie H; Kawatani T; Nakayama E; Matsui T; Kurimura T; Hinuma Y
    Microbiol Immunol; 1985; 29(11):1083-7. PubMed ID: 2869397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition.
    Lusher JM
    Am J Med; 1991 Nov; 91(5A):30S-34S. PubMed ID: 1746594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical analysis of 4 Chinese hemophiliacs with human immunodeficiency virus infection].
    Tang DJ; Xu YH; Dai D
    Zhonghua Nei Ke Za Zhi; 1989 Aug; 28(8):466-8, 509. PubMed ID: 2513171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Oral administration of factor VIII or IX concentrate preparation].
    Sakuragawa N
    Rinsho Ketsueki; 1985 Jul; 26(7):1086-9. PubMed ID: 3932721
    [No Abstract]   [Full Text] [Related]  

  • 57. [Prevalence of inhibitors in hemophiliacs with reference to the transfusion of blood products (author's transl)].
    Kamiya T
    Rinsho Byori; 1978; 26(4):291-7. PubMed ID: 671775
    [No Abstract]   [Full Text] [Related]  

  • 58. [Anti-HTLV-III antibodies in hemophiliacs treated with concentrates of factors VIII or IX].
    Aznar JA; Granda D; Jorquera J; González-Molina A; Carmona E; Peiró A; Gobernado M
    Sangre (Barc); 1985; 30(5):934-5. PubMed ID: 3937254
    [No Abstract]   [Full Text] [Related]  

  • 59. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
    Blatt PM; White GC; McMillan CW; Webster WP
    JAMA; 1984 Jan; 251(1):67. PubMed ID: 6418898
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.